Small cell lung cancer – Patient Worthy

Breakthrough Lung Cancer Therapy Advances: Ifinatamab Deruxtecan Receives FDA Priority Review for Small Cell Lung Cancer

Post author:Bree Clare
Post published:April 22, 2026
Post category:Small cell lung cancer

Daiichi Sankyo and Merck announced a significant regulatory milestone with the FDA's acceptance and Priority Review of ifinatamab deruxtecan (I-DXd), a potentially first-in-class therapeutic targeting an innovative cancer pathway. According…

source: shutterstock.com

Analysis: Reasons for Small Cell Lung Cancer Patients Refusing Treatment

Post author:Rose Duesterwald
Post published:November 8, 2023
Post category:Small cell lung cancer

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

source: shutterstock.com

November is Lung Cancer Awareness Month

Post author:James Moore
Post published:November 3, 2023
Post category:Lung Cancer Small cell lung cancer

The month of November is recognized around the world as Lung Cancer Awareness Month, a time to advocate and spread awareness about lung cancer. This form of cancer is not…

kalhh / Pixabay

A Combination of Benmelstobart, Anlotinib, and Chemotherapy Improves Survival Rates in SCLC, Study Suggests

Post author:Jessica Lynn
Post published:October 16, 2023
Post category:Small cell lung cancer

Advancing patient outcomes hinges on the development of targeted treatments, particularly in conditions with grim prognoses such as small cell lung cancer (SCLC), which typically has a life expectancy…

oracast / Pixabay

SNB-101 Nabs Orphan Drug Status for SCLC

Post author:Jessica Lynn
Post published:July 24, 2023
Post category:Small cell lung cancer Timely

According to an article from Akosua Mireku of Pharmaceutical Technology, the U.S. Food and Drug Administration recently granted Orphan Drug designation to SNB-101, a potential therapy for people living with…

kalhh / Pixabay

Researchers Identify Gene that Activates P-Subtype SCLC

Post author:Jessica Lynn
Post published:November 3, 2022
Post category:Small cell lung cancer

Unfortunately, there are no cures - nor effective treatment options - for individuals with P-subtype small cell lung cancer (SCLC). This subtype is notoriously treatment-averse; it is also relatively…

Photo by Towfiqu barbhuiya on Unsplash

Senaparib and Temozolomide Earn Orphan Drug Designation for SCLC

Post author:Jessica Lynn
Post published:September 12, 2022
Post category:Small cell lung cancer

Have you ever heard of Orphan Drug designation? This designation is intended to spur research and development into drugs or biologics for rare diseases. Orphan Drug designation is granted…

https://unsplash.com/photos/Y14ONzYtxb4

Iadademstat for SCLC Earns Orphan Drug Designation

Post author:Jessica Lynn
Post published:June 9, 2022
Post category:Small cell lung cancer

In the United States, the FDA grants Orphan Drug designation to drugs or biologics intended to treat, diagnose, or prevent rare conditions. A rare disease or condition is defined as…

source: pixabay.com

Ronnie Wood of the Rolling Stones Faced Small Cell Lung Cancer During COVID

Post author:James Moore
Post published:May 6, 2021
Post category:Small cell lung cancer

According to a story from MSN, 73 year old Ronnie Wood of the Rolling Stones recently discussed in an interview his struggle with small cell lung cancer during the COVID-19…

2020 Brought Exciting Advances in Lung Cancer Care

Post author:Rose Duesterwald
Post published:January 27, 2021
Post category:Small cell lung cancer

Although advances in lung cancer care were overshadowed this year by news about the pandemic, Dr. Jennifer Carlisle’s recent interview with Oncology gave details of spectacular advances in lung cancer…

source: pixabay.com

Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation

Post author:James Moore
Post published:October 22, 2020
Post category:Acute Myeloid Leukemia Rare Disease Small cell lung cancer

According to a story from BioSpace, the biotechnology company Ascentage Pharma announced that two of its investigational treatments have recently received Orphan Drug designation from the US Food and Drug…

source: pixabay.com

New Treatment for Small Cell Lung Cancer Cleared Under Accelerated Approval

Post author:James Moore
Post published:June 18, 2020
Post category:Small cell lung cancer

According to a story from Medpage Today, the US Food and Drug Administration has approved the drug lurbinectedin (marketed as Zepzelca), developed by Jazz Pharmaceuticals, as a treatment for metastatic…

Breakthrough Lung Cancer Therapy Advances: Ifinatamab Deruxtecan Receives FDA Priority Review for Small Cell Lung Cancer

Analysis: Reasons for Small Cell Lung Cancer Patients Refusing Treatment

November is Lung Cancer Awareness Month

A Combination of Benmelstobart, Anlotinib, and Chemotherapy Improves Survival Rates in SCLC, Study Suggests

SNB-101 Nabs Orphan Drug Status for SCLC

Researchers Identify Gene that Activates P-Subtype SCLC

Senaparib and Temozolomide Earn Orphan Drug Designation for SCLC

Iadademstat for SCLC Earns Orphan Drug Designation

Ronnie Wood of the Rolling Stones Faced Small Cell Lung Cancer During COVID

2020 Brought Exciting Advances in Lung Cancer Care

Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation

New Treatment for Small Cell Lung Cancer Cleared Under Accelerated Approval

Let’s Work Together!

Keep Up to Date

Learn More